Overview

Savolitinib vs. Sunitinib in MET-driven PRCC.

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Hutchinson MediPharma (HMP)

Treatments:

Sunitinib